This extensive sample collection allowed us to examine ADAM8 expression for the first time in breast cancer subtypes beyond TNBC (HR−/HER2−), including HR−/HER2+, HR+/HER2− and HR+/HER2+, that we had never examined previously. Here, ADAM8 is linked to breast carcinoma.